Taking a statin while undergoing androgen deprivation therapy (ADT) for prostate cancer appears to pay off when it comes to delaying disease progression.
Patients who were diagnosed early on in the study, or who received endocrine therapy or radical prostatectomy, exhibited a lower HR for mortality vs other patients with PC.
Men who take statins before or after a prostate cancer diagnosis have a significantly reduced risk of dying from the disease.
Stronger effect on prostate cancer-linked, all-cause mortality for those with prediagnostic use.
There is doubt around whether statins can prevent some cancers, but there are data to support their effect on cancer mortality.
Use of statins in patients with colorectal cancer associated with reduced colorectal cancer-specific mortality.
Statin therapy may slow prostate growth in men with an elevated PSA level and a negative prostate biopsy, according to findings presented at the American Urological Association 2012 annual meeting.
Statin use by men receiving androgen deprivation therapy for advanced PCa was associated with decreased risk of overall and cancer-specific mortality.
Statins may slow down prostate cancer in men who are also on androgen deprivation therapy (ADT).
Variants of gene SLCO2B1 associated with progression and survival among patients undergoing androgen deprivation therapy (ADT) for prostate cancer.